Citadel Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Citadel Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-199,800	Closed	-$10.5M	–	14831
2026 Q1	$10.5M	Buy	199,800 +59,500	+42%	+$2.44M	﹤0.01%	3179
2025 Q4	$5.67M	Buy	140,300 +84,500	+151%	+$1.95M	﹤0.01%	4093
2025 Q3	$419K	Buy	+55,800	New	+$356K	﹤0.01%	9554
2025 Q2	–	Sell	-118,700	Closed	-$328K	–	15049
2025 Q1	$328K	Sell	118,700 -78,800	-40%	-$322K	﹤0.01%	9391
2024 Q4	$1.09M	Buy	197,500 +68,100	+53%	+$461K	﹤0.01%	6821
2024 Q3	$1.08M	Buy	129,400 +65,500	+103%	+$539K	﹤0.01%	6729
2024 Q2	$435K	Buy	63,900 +56,500	+764%	+$342K	﹤0.01%	8334
2024 Q1	$48.5K	Sell	7,400 -8,300	-53%	-$54.2K	﹤0.01%	12197
2023 Q4	$102K	Sell	15,700 -3,700	-19%	-$19.6K	﹤0.01%	10917
2023 Q3	$97.6K	Buy	19,400 +200	+1%	+$1.27K	﹤0.01%	10932
2023 Q2	$168K	Buy	+19,200	New	+$224K	﹤0.01%	10154

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's TERN Position: Q2 2026 in Review

Citadel Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 3,218,810 shares — an estimated $170M sold.

Citadel Advisors first reported a position in TERN in Q1 2021 and held it in 17 quarters. The position peaked at $170M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Citadel Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 3,218,810 Terns Pharmaceuticals shares in Q2 2026, an estimated $170M.
Citadel Advisors first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 17 quarters.
Citadel Advisors's Terns Pharmaceuticals position peaked at $170M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.